Analyst consensus rating
Travere Therapeutics Analyst Rating: Strong Buy
Direct answer
Travere Therapeutics's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.21.
Forecast evidence checked October 5, 2026.
Get free Travere Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $56.93
- Average price target
- $75.21
- High price target
- $90.00
- Low price target
- $62.00
- Low target gap
- +8.9%
- Target upside
- +32.1%
- High target gap
- +58.1%
- Target range width
- 49.2%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- October 5, 2026
- Valid through
- October 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Travere Therapeutics?
Travere Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $75.21.
How far are Travere Therapeutics's low and high targets from the recorded price?
The low target implies +8.9%, while the high target implies +58.1%.
How many analysts are included in Travere Therapeutics's consensus?
The verified consensus includes 14 analysts.
How is Travere Therapeutics's target upside or downside calculated?
The average target of $75.21 is divided by the recorded price of $56.93, then one is subtracted to produce +32.1%. This does not guarantee a future return.
When was Travere Therapeutics's analyst forecast verified?
The data was verified on 2026-10-05. The dataset is valid through 2026-10-12.